ArticleJournal of hepatocellular carcinoma2026
Prognostic Relevance of Neddylation-Related Genes in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Targeting neddylation offers a potential therapeutic strategy for hepatocellular carcinoma (HCC). This retrospective study aims to identify genes linked to HCC prognosis associated with neddylation through bioinformatics. Patients and Methods: The research used publicly available datasets. Neddylation-related genes and survival-associated differentially expressed genes (DEGs) were intersected to identify key genes, which underwent enrichment analysis. Least absolute selection and shrinkage operator (LASSO)-Cox and multivariate Cox regression analyses were performed to identify prognostic genes and build a risk model. Potential mechanisms were explored via immune microenvironment and single-cell analysis. Finally, prognostic gene expression was validated in clinical tumor samples using real-time quantitative PCR (RT-qPCR). Results: Through methodical investigation, 62 intersection genes were found, mainly enriched in "DNA duplex unwinding" and "p53 signaling pathway". Six prognostic genes were further determined (SOCS2, DIRAS2, LPL, KRT17, BFSP1, and POF1B). RT-qPCR results confirmed the downregulation of SOCS2 and the upregulation of DIRAS2, LPL, KRT17, BFSP1, and POF1B in HCC. Risk prediction model based on these genes exhibited high predictive accuracy. Subsequently, analysis of the immunological microenvironment showed that the infiltration levels of 8 immune cell types varied significantly among risk categories. M0 macrophages had the highest negative correlation with SOCS2 and the strongest positive association with DIRAS2. Single-cell analysis showed that SOCS2 had higher expression levels in endothelial cells and significant differential expression in most cellular classifications. Conclusion: Six prognosis-associated genes (SOCS2, DIRAS2, LPL, KRT17, BFSP1, and POF1B) as predictive biomarkers for HCC were identified, and a high-accuracy risk model was developed, providing predictive and prognostic references for HCC risk stratification and clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.